Have a personal or library account? Click to login
Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? Cover

Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?

Current Issues in Pharmacy and Medical Sciences
Volume 30 (2017): Issue 4 (December 2017)
By:
Open Access
|Mar 2018
DOI: https://doi.org/10.1515/cipms-2017-0040 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Journal RSS Feed
Language: English
Page range: 207 - 210
Submitted on: Dec 18, 2017
Accepted on: Dec 29, 2017
Published on: Mar 9, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
peritoneal neoplasms,
hyperthermia,
induced,
stomach neoplasms,
cytoreduction surgical procedures,
induction chemotherapy,
laparoscopy
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Pharmacology, toxicology,
Pharmacy,
Pharmacy, other

© 2018 Sebastian Blaj, Pompiliu Piso, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 30 (2017): Issue 4 (December 2017)